A citation-based method for searching scientific literature

Yuka Tosaka, Akio Kanazawa, Fuki Ikeda, Mayu Iida, Junko Sato, Kazuhisa Matsumoto, Toyoyoshi Uchida, Yoshifumi Tamura, Takeshi Ogihara, Tomoya Mita, Tomoaki Shimizu, Hiromasa Goto, Chie Ohmura, Yoshio Fujitani, Hirotaka Watada. Int J Endocrinol 2015
Times Cited: 10







List of co-cited articles
37 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
236
60

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
233
60

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
268
50

Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes.
Tatsuhiko Urakami, Remi Kuwabara, Masako Aoki, Misako Okuno, Junichi Suzuki. Endocr J 2016
12
50

Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus.
Yoshiki Kusunoki, Tomoyuki Katsuno, Kana Miyakoshi, Takashi Ikawa, Rie Nakae, Fumihiro Ochi, Masaru Tokuda, Takafumi Akagami, Kazuki Murai, Masayuki Miuchi,[...]. Diabetes Ther 2013
21
50

Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
S Galasso, A Facchinetti, B M Bonora, V Mariano, F Boscari, E Cipponeri, A Maran, A Avogaro, G P Fadini, D Bruttomesso. Nutr Metab Cardiovasc Dis 2016
17
50

Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
Manaho Komuro, Gaku Inoue, Mitsuhisa Tabata, Yoshifumi Yamada, Koichiro Atsuda, Hajime Matsubara, Junichiro Irie, Junichi Uchida, Chikako Nakajima, Hisa Izumi,[...]. J Diabetes Sci Technol 2015
11
40

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
40


Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
Chiho Yamamoto, Hideaki Miyoshi, Yutaka Fujiwara, Reina Kameda, Mei Ichiyama, Hiroshi Nomoto, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi. Endocr J 2016
15
40


Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
114
40

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
145
30

Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.
Ryo Iga, Hiroshi Uchino, Ken Kanazawa, Shuki Usui, Masahiko Miyagi, Naoki Kumashiro, Hiroshi Yoshino, Yasuyo Ando, Takahisa Hirose. Diabetes Ther 2017
19
30


Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger. Diabetes 2004
409
20

Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era.
Geremia B Bolli, Anna Marinelli Andreoli, Paola Lucidi. Diabetes Technol Ther 2011
18
20



The past, present, and future of basal insulins.
Jeremy Pettus, Tricia Santos Cavaiola, William V Tamborlane, Steven Edelman. Diabetes Metab Res Rev 2016
41
20

Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus.
Rie Nakae, Yoshiki Kusunoki, Tomoyuki Katsuno, Masaru Tokuda, Takafumi Akagami, Kazuki Murai, Tomoya Hamaguchi, Jun-Ichiro Miyagawa, Mitsuyoshi Namba. Drugs R D 2014
6
33

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
224
20





Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Bernard Zinman, Steven P Marso, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Ann Marie Ocampo Francisco,[...]. Diabetologia 2018
83
20

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
139
20

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Kåre I Birkeland, Philip D Home, Ulrich Wendisch, Robert E Ratner, Thue Johansen, Lars A Endahl, Karsten Lyby, Johan H Jendle, Anthony P Roberts, J Hans DeVries,[...]. Diabetes Care 2011
125
20

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
Nandu Thalange, Larry Deeb, Violeta Iotova, Tomoyuki Kawamura, Georgeanna Klingensmith, Areti Philotheou, Janet Silverstein, Stefano Tumini, Ann-Marie Ocampo Francisco, Ona Kinduryte,[...]. Pediatr Diabetes 2015
39
20

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette. JAMA 2006
20

CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY.
Vivian A Fonseca, George Grunberger, Henry Anhalt, Timothy S Bailey, Thomas Blevins, Satish K Garg, Yehuda Handelsman, Irl B Hirsch, Eric A Orzeck, Victor Lawrence Roberts,[...]. Endocr Pract 2016
105
20

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring.
Richard M Bergenstal, Roy W Beck, Kelly L Close, George Grunberger, David B Sacks, Aaron Kowalski, Adam S Brown, Lutz Heinemann, Grazia Aleppo, Donna B Ryan,[...]. Diabetes Care 2018
158
20

Continuous glucose monitoring and intensive treatment of type 1 diabetes.
William V Tamborlane, Roy W Beck, Bruce W Bode, Bruce Buckingham, H Peter Chase, Robert Clemons, Rosanna Fiallo-Scharer, Larry A Fox, Lisa K Gilliam, Irl B Hirsch,[...]. N Engl J Med 2008
940
20

Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline.
Anne L Peters, Andrew J Ahmann, Tadej Battelino, Alison Evert, Irl B Hirsch, M Hassan Murad, William E Winter, Howard Wolpert. J Clin Endocrinol Metab 2016
100
20

International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
617
20


Time trends in mortality rates in type 1 diabetes from 2002 to 2011.
Marit E Jørgensen, Thomas P Almdal, Bendix Carstensen. Diabetologia 2013
45
10







Insulin degludec: overview of a novel ultra long-acting basal insulin.
S C L Gough, S Harris, V Woo, M Davies. Diabetes Obes Metab 2013
40
10

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
John M Lachin, Saul Genuth, Patricia Cleary, Matthew D Davis, David M Nathan. N Engl J Med 2000
10

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
Satish K Garg, Peter A Gottlieb, Mary E Hisatomi, Anna D'Souza, Andrew J Walker, Kenneth E Izuora, H Peter Chase. Diabetes Res Clin Pract 2004
61
10

Refining basal insulin therapy: what have we learned in the age of analogues?
J H Devries, M Nattrass, T R Pieber. Diabetes Metab Res Rev 2007
73
10

Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes.
Linda A Gonder-Frederick, Karen M Schmidt, Karen A Vajda, Megan L Greear, Harsimran Singh, Jaclyn A Shepard, Daniel J Cox. Diabetes Care 2011
140
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.